Neuroprotective effects of recombinant human erythropoietin in the developing brain of rat after lithium-pilocarpine induced status epilepticus

Brain and Development

Volumn 34, Issue 3, 2012, Pages 189-195

  Sözmen, Şule Çaĝlayan ^a   Kurul, Semra Hiz ^a   Yiş, Uluç ^b   Tuĝyan, Kazim ^a   Baykara, Başak ^a   Yilmaz, Osman ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; LITHIUM; PILOCARPINE; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN DEVELOPMENT; BRAIN NERVE CELL; BRAIN TISSUE; CELL DEATH; CONTROLLED STUDY; DENTATE GYRUS; EPILEPTIC STATE; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA2 REGION; HIPPOCAMPAL CA3 REGION; HISTOPATHOLOGY; MALE; NEUROPROTECTION; NONHUMAN; RAT;

ANIMALS; APOPTOSIS; CONVULSANTS; ERYTHROPOIETIN; HIPPOCAMPUS; HUMANS; IN SITU NICK-END LABELING; LITHIUM; MALE; NEURONS; NEUROPROTECTIVE AGENTS; PILOCARPINE; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; STATUS EPILEPTICUS;

EID: 84857033407     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2011.05.002     Document Type: Article

References (36)

1. Blume W.T., Lüders H.O., Mizrahi E., Tassinari C., van Emde Boas W., Engel J. Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology. Epilepsia 2001, 42:1212-1218.
2. Sillanpää M., Shinnar S. Status epilepticus in a population-based cohort with childhood-onset epilepsy in Finland. Ann Neurol 2002, 52:303-310.
3. Scantlebury M.H., Heida J.G., Hasson H.J., VelíŠková J., VelíŠek L., Galanopoulou A.S., et al. Age-dependent consequences of status epilepticus: animal models. Epilepsia 2007, 48:75-82.
4. Araki T., Simon R.P., Taki W., Lan J.Q., Henshall D.C. Characterization of neuronal death induced by focally evoked limbic seizures in the C57BL/6 mouse. J Neurosci Res 2002, 69:614-621.
5. Holmes M.D., Silbergeld D.L., Drouhard D., Wilensky A.J., Ojemann L.M. Effect of vagus nerve stimulation on adults with pharmacoresistant generalized epilepsy syndromes. Seizure 2004, 13:340-345.
6. Holmes G.L. Clinical evidence that epilepsy is a progressive disorder with special emphasis on epilepsy syndromes that do progress. Adv Neurol 2006, 97:323-331.
7. Pitkänen A., Kharatishvili I., Karhunen H., Lukasiuk K., Immonen R., Nairismägi J., et al. Epileptogenesis in experimental models. Epilepsia 2007, 48:13-20.
8. Naegele J.R. Neuroprotective strategies to avert seizure-induced neurodegeneration in epilepsy. Epilepsia 2007, 48:107-117.
9. Pitkänen A. Drug-mediated neuroprotection and antiepileptogenesis. Anim Data Neurol 2002, 59:27-33.
10. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992, 72:449-489.
11. Chin K., Yu X., Beleslin-Cokic B., Liu C., Shen K., Mohrenweiser H.W., et al. Production and processing of erythropoietin receptor transcripts in brain. Brain Res Mol Brain Res 2000, 81:29-42.
12. Brines M.L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N.C., Cerami C., et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000, 97:10526-10531.
13. Bernaudin M., Marti H.H., Roussel S., Divoux D., Nouvelot A., MacKenzie E.T., et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999, 19:643-651.
14. Sakanaka M., Wen T.C., Matsuda S., Masuda S., Morishita E., Nagao M., et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998, 95:4635-4640.
15. Grasso G., Buemi M., Alafaci C., Sfacteria A., Passalacqua M., Sturiale A., et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci USA 2002, 99:5627-5631.
16. Gorio A., Gokmen N., Erbayraktar S., Yilmaz O., Madaschi L., Cichetti C., et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 2002, 99:9450-9455.
17. Junk A.K., Mammis A., Savitz S.I., Singh M., Roth S., Malhotra S., et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 2002, 99:10659-10664.
18. Yiş U., Kurul S.H., Kumral A., Tuĝyan K., Cilaker S., Yi{dotless}lmaz O., et al. Effect of erythropoietin on oxygen-induced brain injury in the newborn rat. Neurosci Lett 2008, 448:245-249.
19. Acharya M.M., Hattiangady B., Shetty A.K. Progress in neuroprotective strategies for preventing epilepsy. Prog Neurobiol 2008, 84:363-404.
20. Glien M., Brandt C., Potschka H., Voigt H., Ebert U., Löscher W. Repeated low- dose treatment of rats with pilocarpine: low mortality but high proportion of rats developing epilepsy. Epilepsy Res 2001, 46:111-119.
21. Suchomelova L., Baldwin R.A., Kubova H., Thompson K.W., Sankar R., Wasterlain C.G. Treatment of experimental status epilepticus in immature rats: dissociation between anticonvulsant and antiepileptogenic effects. Pediatr Res 2006, 59:237-243.
22. Racine R. Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972, 32:281-294.
23. Yang J., Huang Y.G., Yu X., Sun H., Li Y.N., Deng Y.C. Erythropoietin preconditioning suppresses neuronal death following status epilepticus in rats. Acta Neurobiol Exp 2007, 67:141-148.
24. Paxinos G., Watson G. The rat brain in stereotaxic coordinates 1986, Academic Press, New York. 2nd ed.
25. Houser C.R., Miyashiro J.E., Swartz B.E., Walsh G.O., Rich J.R., Delgado-Escueta A.V. Altered patterns of dynorphin immunoreactivity suggest mossy fiber reorganization in human hippocampal epilepsy. J Neurosci 1990, 10:267-282.
26. Clark S., Wilson W.A. Mechanisms of epileptogenesis. Adv Neurol 1999, 79:607-630.
27. Narkilahti S., Nissinen J., Pitkänen A. Administration of caspase 3 inhibitor during and after status epilepticus in rat: effect on neuronal damage and epileptogenesis. Neuropharmacology 2003, 44:1068-1088.
28. Bartesaghi S., Marinovich M., Corsini E., Galli C.L., Viviani B. Erythropoietin: a novel neuroprotective cytokine. Neurotoxicology 2005, 26:923-928.
29. Sola A., Wen T.C., Hamrick S.E.G., Ferriero D.M. Potential for protection and repair following injury to the developing brain: a role for erythropoietin?. Pediatr Res 2005, 57:7R-10R.
30. Jun Y., JiangTao X., YuanGui H., YongBin S., Jun Z., XiaoJun M., et al. Erythropoietin pre-treatment prevents cognitive impairments following status epilepticus in rats. Brain Res 2009, 1282:57-66.
31. Jiang C.M., DU J.M., Liu Z.L., Chen L.Q., Feng M., Yang Y.H., et al. Effects of recombinant human erythropoietin on serum levels of neuron-specific enolase, S-100β protein and myelin basic protein in rats following status epilepticus. Zhongguo Dang Dai Er Ke Za Zhi (Chin J Contemp Pediatr). 2011, 13:50-52. [in Chinese].
32. Chu K., Jung K.H., Lee S.T., Kim J.H., Kang K.M., Kim H.K., et al. Erythropoietin reduces epileptogenic processes following status epilepticus. Epilepsia 2008, 49:1723-1732.
33. Henshall D.C. Apoptosis signalling pathways in seizure-induced neuronal death and epilepsy. Biochem Soc Trans 2007, 35:421-423.
34. Kondratyev A., Gale K. Intracerebral injection of caspase-3 inhibitor prevents neuronal apoptosis after kainic acid-evoked status epilepticus. Brain Res Mol Brain Res 2000, 75:216-224.
35. Wang W.P., Shi Z.Q., Yu J.H., Guo L., Wang L., Han D.L., et al. Effect of recombinant human erythropoietin on hippocampal p-Akt and caspase-9 expressions in rats with status epilepticus and the mechanism. Nan Fang Yi Ke Da Xue Xue Bao 2010, 30:64-69. [in Chinese].
36. Jung K.H., Chu K., Lee S.T., Park K.I., Kim J.H., Kang K.M., et al. Molecular alterations underlying epileptogenesis after prolonged febrile seizure and modulation by erythropoietin. Epilepsia 2011, 52:541-550.